This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


2qj2

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2qj2.gif|left|200px]]
+
{{Seed}}
 +
[[Image:2qj2.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2qj2| PDB=2qj2 | SCENE= }}
{{STRUCTURE_2qj2| PDB=2qj2 | SCENE= }}
-
'''A Mechanistic Basis for Converting a Receptor Tyrosine Kinase Agonist to an Antagonist'''
+
===A Mechanistic Basis for Converting a Receptor Tyrosine Kinase Agonist to an Antagonist===
-
==Overview==
+
<!--
-
Hepatocyte growth factor (HGF) activates the Met receptor tyrosine kinase by binding and promoting receptor dimerization. Here we describe a mechanistic basis for designing Met antagonists based on NK1, a natural variant of HGF containing the N-terminal and the first kringle domain. Through detailed biochemical and structural analyses, we demonstrate that both mouse and human NK1 induce Met dimerization via a conserved NK1 dimer interface. Mutations designed to alter the NK1 dimer interface abolish its ability to promote Met dimerization but retain full Met-binding activity. Importantly, these NK1 mutants act as Met antagonists by inhibiting HGF-mediated cell scattering, proliferation, branching, and invasion. The ability to separate the Met-binding activity of NK1 from its Met dimerization activity thus provides a rational basis for designing Met antagonists. This strategy of antagonist design may be applicable for other growth factor receptors by selectively abolishing the receptor activation ability but not the receptor binding of the growth factors.
+
The line below this paragraph, {{ABSTRACT_PUBMED_17804794}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 17804794 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_17804794}}
==About this Structure==
==About this Structure==
Line 32: Line 36:
[[Category: Hgf/sf]]
[[Category: Hgf/sf]]
[[Category: Hormone/growth factor]]
[[Category: Hormone/growth factor]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 15:02:39 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 20:09:21 2008''

Revision as of 17:09, 28 July 2008

Image:2qj2.png

Template:STRUCTURE 2qj2

A Mechanistic Basis for Converting a Receptor Tyrosine Kinase Agonist to an Antagonist

Template:ABSTRACT PUBMED 17804794

About this Structure

2QJ2 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist., Tolbert WD, Daugherty J, Gao C, Xie Q, Miranti C, Gherardi E, Woude GV, Xu HE, Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14592-7. Epub 2007 Sep 5. PMID:17804794

Page seeded by OCA on Mon Jul 28 20:09:21 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2qj2"
Personal tools